Results 101 to 110 of about 2,969,292 (313)

Duration of adjuvant chemotherapy for stage III colon cancer [PDF]

, 2018
BACKGROUND Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer.
Andre, Thierry, Boukovinas, Ioannis, Grothey, Axel, Iveson, Timothy, Kerr, Rachel, Labianca, Roberto, Meyerhardt, Jeffrey A., Meyers, Jeffrey P., Niedzwiecki, Donna, Paul, James, Renfro, Lindsay A., Sargent, Daniel J., Saunders, Mark, Shi, Qian, Shields, Anthony F., Sobrero, Alberto F., Souglakos, John, Taieb, Julien, Torri, Valter, Vernerey, Dewi, Watanabe, Toshiaki, Yamanaka, Takeharu, Yoshino, Takayuki   +22 more
core   +1 more source

Cancer Gene Therapy

Technology in Cancer Research & Treatment, 2003
Cancer gene therapy is the transfer of genetic material to the cells of an individual with the goal of eradicating cancer cells, both in the primary tumor and metastases. Cancer gene therapy strategies exploit our expanding knowledge of the genetic basis of cancer, thereby allowing rationally targeted interventions at the molecular level.
openaire   +2 more sources

A High‐Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK‐Rearranged Non–Small Cell Lung Cancer

Pediatric Blood &Cancer, EarlyView.
Alberto D. Guerra, Nicholas F. Evageliou, Vandana Batra, Kristen L. Dalton, Stephanie Ortel, Usman Ashraf, Tricia R. Bhatti, Lisa J. States, Lea F. Surrey, Theodore W. Laetsch   +9 more
wiley   +1 more source

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. [PDF]

, 2017
Acquired drug resistance prevents cancer therapies from achieving stable and complete responses. Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer 'persister' cells.
Berens, Michael E, Bole, Dhruv, Dhruv, Harshil D, Eaton, John K, Galeas, Jacqueline, Hangauer, Matthew J, Matov, Alexandre, McCormick, Frank, McManus, Michael T, Ryan, Matthew J, Schreiber, Stuart L, Viswanathan, Vasanthi S   +11 more
core   +1 more source

Enteropathogenic E. coli shows delayed attachment and host response in human jejunum organoid‐derived monolayers compared to HeLa cells

FEBS Letters, EarlyView.
Enteropathogenic E. coli (EPEC) infects the human intestinal epithelium, resulting in severe illness and diarrhoea. In this study, we compared the infection of cancer‐derived cell lines with human organoid‐derived models of the small intestine. We observed a delayed in attachment, inflammation and cell death on primary cells, indicating that host ...
Mastura Neyazi, Pilar Samperio Ventayol, Natalie Burkard, Nicolas Schlegel, Carmen Aguilar, Sina Bartfeld   +5 more
wiley   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Planning for a pandemic: Mitigating risk to radiation therapy service delivery in the COVID‐19 era

Journal of Medical Radiation Sciences, 2020
The novel coronavirus (COVID‐19) has rapidly impacted all of our lives following its escalation to pandemic status on 11 March 2020. Government guidelines and restrictions implemented to mitigate the risk of COVID‐19 community transmission have forced ...
Nigel Anderson, Kenton Thompson, Judy Andrews, Brent Chesson, Alison Cray, Damien Phillips, Michelle Ryan, Sally Soteriou, Glenn Trainor, Nilgun Touma   +9 more
doaj   +1 more source

Advancing Cancer Therapy [PDF]

Nature Cancer, 2021
openaire   +2 more sources

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers

Frontiers in Oncology, 2019
Targeted radiopharmaceuticals for therapeutic use deliver radionuclides directly to tumor anywhere in the body, and therefore, have renewed interest for clinical development in women with disseminated chemorefractory ovarian cancers.
Charles A. Kunos, Jacek Capala, Shanda Finnigan, Gary L. Smith, Susan Percy Ivy   +4 more
doaj   +1 more source